The clinical drugs for AD patients include acetylcholinesterase (AChE) inhibitors, such as the FDA-approved donepezil, rivastigmine, galantamine developed by cholinergic hypothesis (Alzheimer’s & Association 2024); and the FDA-approved memantine, a N-methyl-D-aspartate receptor antagonist by blocking excitotoxic effects of glutamate (Witt et al. 2004). The gene discussed is ACHE; the disease is Alzheimer disease.